Observational studyClinical endocrinology2026
Apparent Bilateral Aldosterone Suppression During Adrenal Vein Sampling: An Artefact of the Liaison Chemiluminescence Immunoassay and Other Causes Revealed by Comparisons With Another Commercial Immunoassay and Mass Spectrometry.
Observational study in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveSubtyping of primary aldosteronism usually requires adrenal vein sampling (AVS). Interpretation can be compromised by apparent bilateral aldosterone suppression (ABAS), which we hypothesised reflects an artefact of the Liaison immunoassay of aldosterone. We therefore compared measurements of aldosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with those by Liaison and iSYS immunoassays.
designObservational multicentre study. PATIENTS: The study involved 216 patients who underwent bilaterally selective non-stimulated AVS. MEASUREMENTS: Adrenal and peripheral venous plasma aldosterone concentrations were measured by Liaison and iSYS immunoassays in 110 and 106 respective samplings compared to LC-MS/MS in all. Ratios of aldosterone-to-cortisol below 1.0 in adrenal versus peripheral vein samples defined relative aldosterone suppression.
resultsAmong all AVS procedures, 9.7% (21/216) of samplings with immunoassay measurements showed ABAS, threefold more (p = 0.0004) than the 3.2% (7/216) with LC-MS/MS. Rates of ABAS were particularly high with the Liaison immunoassay compared to LC-MS/MS (14.5% vs. 0.9%, p < 0.0001) and remained higher after substitution of immunoassay-measured with LC-MS/MS-measured cortisol (10.9% vs. 0.9%, p = 0.0007). Among 106 procedures involving iSYS immunoassay measurements, rates of ABAS at 4.7% were a third (p = 0.0202) those of the Liaison immunoassay and did not differ from LC-MS/MS measurements (5.7%). ABAS confined to LC-MS/MS measurements in one patient was resolved by a second sampling that revealed pronounced aldosterone secretion versus earlier suppression.
conclusionABAS is a relatively common artefact of the Liaison immunoassay of aldosterone. More rarely, ABAS may reflect sampling blood from an adrenal venous tributary that does not drain from the site of excess aldosterone secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.